Deciphera's Qinlock Approved In Europe For Gastric Cancer


The European Commission has approved Deciphera Pharmaceuticals Inc's DCPH Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. 

  • In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib, to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST2.
  • Related Link: Why Did Deciphera Stock Plunge 70% Today?
  • The approval was supported by efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study.
  • The trial demonstrated a median progression-free survival of 6.3 months compared to 1.0 month in the placebo arm.
  • It reduced the risk of disease progression or death by 85% 
  • Price Action: DCPH shares are up 1.64% at $8.64 during the market session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsgastric cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!